

24 November 2022

LGP significantly expands flower portfolio

Highlights:

- LGP Denmark supplies three new high-THC LGP-branded cannabis flower products into Australian market
- New products significantly expand LGP flower portfolio and enhance LGP competitiveness in rapidly growing Australian flower market
- Ownership of supply chain provides LGP with enhanced production availability and reliability and improved cost and quality control




Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) is pleased to announce the arrival of over 6,500 units of three new LGP-branded high-THC medicinal cannabis flower products into the Australian market representing the commercialisation of the Danish facility.

The entry of these products into the Australian market follows an 18-month journey from initial strain development and production at the Company’s Danish operation following LGP’s acquisition of these facilities in July 2021. Paired with LGP’s existing flower offering from its Australian facilities, the new products give LGP’s product suite the enhanced depth and product range required to grow LGP’s share of the rapidly expanding Australian flower market. In addition to these three new products, the Company also anticipates receiving 4,000 units of a fourth new flower product concept offering from its Danish facilities in December this year, with over 10 additional strains in various stages of development intended for supply into the Australian and other markets in the coming quarters.

LGP believes ownership of GMP production facilities and control of the supply chain provides the required reliability, product availability and quality needed to compete across all product and market segments, by including competitive advantages such as brand ownership in underlying strains, reduced subcontractor margins, fewer GMP vendor qualifications, reduced stock out risk, improved quality control, manufacturing economies of scale, and reduced reliance on third parties for market participation. The Company believes these advantages successfully position it and its business model to compete strongly in all key markets including through the transition to the new Australian GMP market requirements in July next year.

**ENDS
BY ORDER OF THE BOARD**



Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Fleta Solomon
Chief Executive Officer
Little Green Pharma
E: f.solomon@lgp.global
T: +61 8 6280 0050



About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m² cultivation and 4,000m² GMP manufacturing facility capable of producing over 30 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

